EVT:ETR
Evotec SE
€2.63
arrow_upward
+0.15%(+0.0040) 1D
10월 20일, 오후 3시 3분 2초 GMT+2 · EUR
search
모든 종목 코드
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_autoEVT의 주요 통계 생성 중...
시가
€2.61
고가
€2.69
저가
€2.60
시가총액
4.72억
평균 거래량
117.95만
거래량
31.06만
52주 최고가
€7.30
52주 최저가
€2.41
EPS
-€1.11
유통 주식수
1.78억
직원 수
4천
시가
€2.61
고가
€2.69
저가
€2.60
시가총액
4.72억
평균 거래량
117.95만
거래량
31.06만
52주 최고가
€7.30
52주 최저가
€2.41
EPS
-€1.11
유통 주식수
1.78억
직원 수
4천
뉴스 기사
웹 소스 및 뉴스 파트너 제공
ad-hoc-news.de
·
5시간 전
Berenberg keeps EUR 3.60 target for Evotec stock
ad-hoc-news.de
·
22시간 전
Evotec stock: November 5, 2026 results date puts Evotec stock on the calendar
프로필
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.
The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more.
On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
Evotec SE에 관한 정보